Related Experiment Videos
Hepatitis B virus in diabetic patients
Acta Diabetologica Latina
|July 1, 1980
Summary
Diabetic patients show similar Hepatitis B surface antigen (HBsAg) rates but higher Hepatitis B core antibody (anti-HBc) levels compared to the general population. This finding, particularly in those on oral medication, requires further investigation.
Area of Science:
- Hepatology
- Endocrinology
- Immunology
Background:
- Diabetes mellitus is a global health concern.
- Hepatitis B virus (HBV) infection is a significant public health issue.
- The interplay between diabetes and HBV infection requires further elucidation.
Purpose of the Study:
- To investigate the prevalence of Hepatitis B virus (HBV) markers in diabetic patients.
- To compare HBV marker profiles between diabetic patients and a healthy control group.
- To explore potential differences in HBV serological markers among diabetic patients receiving different treatments.
Main Methods:
- Serum samples from 149 diabetic patients were analyzed.
- Detection of HBV markers including Hepatitis B surface antigen (HBsAg) and anti-HBc antibodies.
- Comparison of marker prevalence with a normal population cohort.
Main Results:
- No significant difference in HBsAg incidence was observed between diabetic and normal populations.
- Diabetic patients exhibited a significantly higher prevalence of anti-HBc antibodies.
- This elevated anti-HBc antibody level was particularly noted in diabetic patients undergoing oral hypoglycemic therapy.
Conclusions:
- Diabetic individuals, especially those on oral hypoglycemic agents, may have altered Hepatitis B virus (HBV) immune responses.
- The observed higher prevalence of anti-HBc antibodies in diabetics warrants further research to understand the underlying mechanisms.
- The unexplained differences highlight a potential link between diabetes, its treatment, and HBV serological profiles.